The Nichols & Pratt Advisers LLP MA reaches $3,411,000 position of Pfizer Inc. (PFE)

The Nichols & Pratt Advisers LLP MA reaches $3,411,000 position  of Pfizer Inc. (PFE)

Nichols & Pratt Advisers LLP MA reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 96,872 shares of the biopharmaceutical company’s stock after selling 3,400 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Pfizer were worth $3,411,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Stelac Advisory Services LLC purchased a new position in shares of Pfizer during the second quarter worth about $110,000. Catamount Wealth Management boosted its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Commonwealth Financial Services LLC boosted its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the last quarter. Finally, Financial Management Professionals Inc. boosted its stake in Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 993 shares during the last quarter. Institutional investors own 69.65% of the company’s stock.

Shares of Pfizer Inc. (NYSE:PFE) traded down 0.27% on Friday, reaching $33.56. 14,819,706 shares of the company were exchanged. The company has a market capitalization of $203.56 billion, a price-to-earnings ratio of 29.75 and a beta of 0.86. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The company’s 50-day moving average is $34.29 and its 200-day moving average is $34.19.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. Pfizer’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.56 earnings per share. On average, equities analysts expect that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 3.58%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.

A number of analysts have weighed in on PFE shares. Jefferies Group set a $41.50 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Thursday, July 14th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price on the stock in a research note on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 3rd. Argus reaffirmed a “buy” rating and set a $39.00 target price on shares of Pfizer in a research note on Tuesday. Finally, Credit Suisse Group AG reaffirmed an “outperform” rating and set a $40.00 target price on shares of Pfizer in a research note on Monday, August 22nd. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer currently has an average rating of “Buy” and an average target price of $38.78.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Related posts

Leave a Comment